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Non-alcoholic fatty liver disease (NAFLD) is the most common cause of 
chronic liver disease worldwide, affecting 24% of the population, and is impacting 
on global public health care with a considerable financial burden (1). NAFLD 
encompasses a wide disease spectrum ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Patients with simple 
steatosis typically do not develop liver-related complications, whereas patients 
with NASH are at increased risk of hepatic and extra-hepatic mortality. 
Furthermore, NAFLD is associated with an increased risk of type 2 diabetes, 
cardiovascular disease and cancer (2). In addition, NASH is the second leading 
cause of cirrhosis in adult patients on the liver transplant waiting list in the United 
States (3,4). 
In the past decade, there has been immense progress in the understanding of 
the pathogenesis of NAFLD, which led to an exponential increase in clinical trials 
of pharmacotherapies targeting identified pathways. Despite this progress, there is 
still no approved medication for treating NASH. The recent article by Friedman et 
al. extensively reviews current evidence on risk factors, pathogenesis and 
treatment of NAFLD, with an emphasis in preclinical models and ongoing phase II 
and III pharmacological clinical trials (5). As the authors point out, the traditional 
two-hit hypothesis for the pathogenesis of NASH is now outdated. A multi-hit 
theory has been proposed, that reflects the diverse potential pathways for the 
development and progression of NAFLD. Interplay among multiple insults, 
including insulin resistance, adipokines and inflammatory cytokines secreted from 
the adipose tissue, intestinal microbiota, genetic and epigenetic factors, oxidative 
stress, environmental and dietary factors lead to the development of NAFLD and to 
the progression to NASH and fibrosis (6). Different mechanisms of injury might 
prevail in individuals, which if true will complicate the therapeutic landscape, as 
future treatments might not be effective for all patients. A better understanding of 
such pathways will open the opportunity to develop novel non-invasive diagnostic 
tests and targeted pharmacological treatments.  
Multiple agents are currently being investigated and have been summarized 
by the authors in their article (7-10). Novel drugs, such as obeticholic acid, 
selonsertib, elafibranor and cenicriviroc have shown encouraging results in phase 
II and are currently in phase III trials, with expected results within the next 1-4 
years. The primary endpoints of phase IIb and III trials are focused on NASH 
resolution without worsening of liver fibrosis or improvement/regression in 
fibrosis without worsening of NASH. Commenting on the trial endpoints is beyond 
the scope of this editorial, however NAS score is a problematic surrogate treatment 
endpoint because of its high inter- and intra-observer variability and its lack of 
association with clinical events. Even though the results of these trials were so far 
promising in phase II, unfortunately only 10-30% of treated patients show a net 
benefit compared to placebo. Additionally, none of the agents have a proven 
advantage on long-term outcomes. The issue is further complicated by the long 
natural history of NAFLD. Combination therapies might have greater response, 
however this will need to be proven in future studies. There is therefore an urgent 
need to improve the efficacy of treatment strategies for NASH.  
The review did not comment on the current mainstay strategy for NASH 
treatment, which is weight reduction through lifestyle interventions. These include 
a combination of increase in exercise/physical activity and caloric restriction and 
should be individually tailored. Weight loss of ≥7% of total body weight is 
associated with improvement in histologic features of NASH, while a weight loss 
of  ≥10% is associated with fibrosis regression regardless of the method used (11). 
Previous randomized controlled trials in NASH reported a histological 
improvement in the placebo arm that ranges between 10-30%. Although it is 
difficult to fully explain this, it is probable that a significant proportion of these 
patients improved due to the successful implementation of lifestyle changes. 
Unhealthy lifestyle habits, such as smoking might be associated with more severe 
liver fibrosis and increased incidence of cardiovascular outcomes (12).  However, 
this approach is difficult to sustain, as most patients have low compliance to 
weight loss maintenance in the long term. To improve the efficacy and 
sustainability of this strategy, a multidisciplinary team approach is needed that 
includes primary care physicians, hepatologists, dietitians, physical trainers and 
psychologists. Bariatric surgery is a promising option for reducing weight and 
metabolic complications. Although it is not yet an established therapy for NASH 
and more data are required to support its use for the liver disease component, some 
experts suggest considering bariatric surgery in morbidly obese non-cirrhotic 
patients who failed lifestyle modifications (13). 
In conclusion, the growing burden of NAFLD worldwide is an emerging 
concern. NASH is classified as a medical condition of an immediate unmet 
therapeutic need. Therefore continuous research is required in order to better 
understand its pathogenesis, develop of non-invasive markers of severity and 
identify new therapeutic targets. 
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